Monday I did a post in response to an item that appeared in the Secondhand Smoke Blog by Wesley J. Smith where he invoked the opponents of ESC research favorite term to contrast so-called adult stem cell research with ESC research. In addition, he implied that George W. Bush deserved some of the credit for […]
Lessons from getting attacked by ESC research opponents Read More »
This is just the first in a series “Tales from the hood” about the stories of the stem cell scientists at the front lines of research. What really goes on in labs? After spending nearly half of my life being a scientist in one form or another including much time studying stem cells, I have
Tales from the Hood: what really goes on in research labs? Read More »
It’s great to talk to Irv Weissman. It has been a week to think about mentors and I posted somewhat autobiographically on how to find and be a good mentor a few days ago. Also along these lines, I asked one of the great mentors of all time, Irv Weissman, about his early career and
Irv Weissman, his early career & mentors that made the difference Read More »
I have posted before about publishing trends in the iPS cell field here and in here…. but where do things stand today? Here, I provide an important update. What’s going on now? Here I provide answers to the key questions. How many papers are there on iPS cells? An interesting and unexpected trend for
Everything you need to know about publishing in the iPS cell field Read More »
What’s up with Advanced Cell Technology (ACT) and Geron? ACT announced today that it has treated two patients in its clinical trials: one for Stargardt’s Macular Dystrophy (see official trial page for a lot more info) and one for Dry Age-Related Macular Degeneration (see official trial page here for a lot more info). The patients underwent
The latest scoop on ACT and Geron Read More »
What is ISSCR doing about unproven stem cell clinics? One of the greatest and most infuriating ironies of the stem cell-based regenerative medicine universe is that while the FDA strictly regulates the progress of therapy development by Advanced Cell Technology (ACT) and Geron and other legitimate companies, at the same time mysteriously the FDA essentially
ISSCR KO’d in round one versus unproven clinics: where’s the FDA? Read More »
Two companies, Advanced Cell Technology (ACT) and Geron, both HQ’d here in California, have FDA-approved early stage clinical trials in the works. Geron’s trial has already started and reportedly now has enrolled at least two patients. The trial is of course for the safety of Geron’s GRNOPC1 oligodendrocyte product made from human ES cells for
Advanced Cell Technology and Geron: allies or competitors? Read More »
Yamanaka may have found a way to give exogenous Myc the boot from the iPS cell universe. It has always been a frustration in the iPS cell field that Myc, a proto-oncogene, is so important for reprogramming. Yes, you can make iPS cells (especially mouse) without Myc, but it can be orders of magnitude harder,
New iPS cell method: drop Myc or not yet? Read More »
A Federal Appeals Court ruled 2-1 today to overturn Judge Lamberth’s injunction against federal funding of ES cell research. Great news! You can read the decision here (warning: big pdf). A key part of the ruling was the following: “the plaintiffs are unlikely to prevail because Dickey-Wicker is ambiguous and the NIH seems reasonably to
Victory for science and patients: what the appeals court ES cell ruling means (UPDATE) Read More »
The tragic 9.0 earthquake and tsunamis that hit Japan a few weeks ago are having lasting consequences not only for Japan, but also for the world via radiation. One area of particular concern is the radiation that has leaked and is continuing to leak from the damaged nuclear reactors. At this point, the radiation
A reality check on the radiation spreading across the globe Read More »